

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司
NORTHEAST TIGER PHARMACEUTICAL CO., LTD.*
(A joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8197)

STATUS UPDATE OF THE PLACING OF H SHARES

Reference is made to the Company's announcements dated 24 May 2016, 27 May 2016 and 24 August 2016 (the "**Announcements**") relating to the Placing. Terms used herein shall have the same meanings as defined in the Announcements unless otherwise stated.

STATUS UPDATE OF THE PLACING

The Board is pleased to announce that save for the approval of the Stock Exchange in relation to the grant of listing of, and permission to deal in the Placing Shares, the other condition as set out in the Placing Agreement and Supplemental Agreement (collectively, the "**Agreements**") has been satisfied in accordance with the terms and conditions of the Agreements. Since the General Mandate had expired when the Company and the Placing Agent entered into the Supplemental Agreement on 23 August 2016, an aggregate of 41,400,000 H shares, will be, subject to satisfaction of the aforesaid condition in this announcement, allotted and issued under the general mandate granted to the Board, which was resolved as Resolution No. 5 in the annual general meeting held on 30 May 2016, representing approximately 20% and 5.54%, respectively, of the existing issued H-Shares and the existing issued share capital of the Company as at completion at the Placing Price of HK\$0.97 per H Share to no less than six Placees, who and whose ultimate beneficial owners are third parties independent of and not connected with the Company or its connected persons. None of the Placees will become a substantial shareholder of the Company immediately after the completion of the Placing.

The aggregate gross proceeds from the Placing will amount to approximately HK\$40,158,000 and the aggregate net proceeds from the Placing (after deducting all applicable costs and expenses, including commission and levies) will be expected to amount to approximately HK\$38,158,000.

Following the completion of the Placing, the total number of issued Shares of the Company will be increased from 746,654,240 Shares to 788,054,240 Shares and the total number of H Shares in issue will be increased from 207,000,000 Shares to 248,400,000 Shares.

By Order of the Board
東北虎藥業股份有限公司
Northeast Tiger Pharmaceutical Co., Ltd.*
Chairman
Wang Shaoyan

Jilin, the PRC, 9 September 2016

As at the date of this announcement, the Company's executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company's non-executive directors are Guo Aiqun and Cao Yang and the Company's independent non-executive directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

* for identification purposes only